Kailera Therapeutics, Inc.
Research Kailera Therapeutics, Inc. (KLRA) on Bullrun: market cap USD 1.47B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKLRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.47B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 111.31M
- Free cash flow-USD 77.53M
Valuation Snapshot
latest market cap is USD 1.47B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 148.96M | -USD 122.30M | n/a | -1.26 | USD 160.27M | USD 10.75M | -USD 356.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 1.47B | n/a | n/a | n/a |
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kailera Therapeutics, Inc.'s market cap?
Kailera Therapeutics, Inc.'s market capitalization is USD 1.47B.
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.